Table 1.
Profiles of patients with TAK and healthy controls
| Risk group (n = 31) |
Non-risk group (n = 13) |
Healthy controls (n = 19) |
P value | |
|---|---|---|---|---|
| Age (years) | 48.1 ± 14.6 | 40.3 ± 12.1 | 35.4 ± 9.3 | <0.01a |
| Sex (male/female) | 1/30 | 0/11 | 1/18 | 1.00b |
| Duration of disease (years) | 16.8 ± 11.4 | 15.8 ± 11.1 | ― | 0.97c |
| Average dose of glucocorticoids (mg/day) | 6.3 ± 3.5 | 6.3 ± 4.0 | ― | 0.64c |
| Average CRP (mg/dL) | 0.43 ± 0.77 | 0.14 ± 0.21 | ― | 0.052c |
| Average ESR (mm/h) | 22.6 ± 17.7 | 20.4 ± 20.9 | ― | 0.69c |
| Use of immunosuppressants | 8/31 (25.8%) | 4/13 (30.8%) | ― | 0.73b |
| Use of biologics | 2/31 (6.5%) | 0/13 (0%) | ― | 1.00b |
Values are average ± standard deviation or number of patients. Immunosuppressants: methotrexate (n = 6; n = 4 in the risk group and 2 in the non-risk group) and azathioprine (n = 6; n = 4 in the risk group and 2 in the non-risk group). Biologics: tocilizumab (n = 2)
TAK Takayasu arteritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate
aStatistical analysis performed by one-way analysis of variance.
bStatistical analysis performed by Fisher’s exact test
cStatistical analysis performed by Welch’s t test